DIASTAT ACUDIAL pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich	⤷ Get Started Free	D0899_SIGMA	⤷ Get Started Free
Hangzhou APIChem Technology	⤷ Get Started Free	AC-10561	⤷ Get Started Free
AKos Consulting & Solutions	⤷ Get Started Free	AKOS003367969	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 6, 2025

Introduction

The integrity of pharmaceuticals begins with the quality of their active pharmaceutical ingredients (APIs). For medications such as DIASTAT ACUDIAL, a clinically integral anticonvulsant and mood stabilizer, sourcing high-quality APIs is crucial to ensure safety, efficacy, and regulatory compliance. DIASTAT ACUDIAL, containing diazepam and acudial components, requires a rigorous supply chain process, emphasizing authenticity, purity, and adherence to pharmaceutical standards. This report delineates the landscape of bulk API sources for DIASTAT ACUDIAL, highlighting key suppliers, manufacturing regions, and considerations for quality assurance.

Understanding the API Composition of DIASTAT ACUDIAL

DIASTAT ACUDIAL combines two primary active components:

Diazepam: An anxiolytic, sedative, muscle relaxant, and anticonvulsant primarily used for status epilepticus, anxiety, and muscle spasms.
Acudial (Phenobarbital): A barbiturate employed for seizure control, particularly in epilepsy.

Both APIs must comply with stringent pharmacopoeial standards (e.g., USP, EP, JP) to ensure therapeutic efficacy and patient safety.

Global API Manufacturing Regions

The market for pharmaceutical APIs is geographically dispersed, with leading production hubs:

India
China
Europe (especially Germany and Switzerland)
United States

Each region offers distinct advantages concerning price, regulatory environment, and manufacturing capacity, influencing API sourcing decisions for DIASTAT ACUDIAL.

Major API Suppliers for Diazepam

1. China

China's pharmaceutical API industry is a dominant global supplier, accounting for approximately 40% of worldwide API production capacity [1]. Prominent Chinese manufacturers include:

Zhejiang NHU Co., Ltd.
Recognized for producing high-quality diazepam conforming to USP and EP standards, with extensive GMP certification.
Shenzhen South China Pharmaceutical Co., Ltd.
Supplies diazepam with competitive pricing, primarily exported to global markets.

2. India

India hosts several WHO-GMP compliant API manufacturers who produce diazepam suitable for export and domestic use:

Aurobindo Pharma Ltd.
Offers diazepam APIs with rigorous quality control matching international standards.
Hetero Labs Ltd.
Known for high-volume, cost-effective API manufacturing including diazepam.

3. Europe

European manufacturers focus on high-purity APIs for highly regulated markets:

BASF (Germany)
Produces diazepam API with certified quality, emphasizing environmental compliance.
Dr. Reddy’s Laboratories (India, with European facilities)
Supplies high-grade APIs globally, including diazepam.

4. United States

The U.S. market generally sources APIs from domestic or compliant foreign suppliers, mainly for finished dosage formulations instead of bulk API importation. However, some U.S.-based manufacturers or authorized agents supply diazepam API for compounding or specialty needs.

API Quality Assurance and Regulatory Considerations

When sourcing APIs for DIASTAT ACUDIAL, manufacturers and formulators must prioritize:

GMP Compliance: Ensures the API is manufactured under Good Manufacturing Practices, reducing contamination and batch-to-batch variability.
Pharmacopoeial Standards: APIs should meet USP, EP, or JP specifications for purity, potency, and stability.
Batch Consistency and Traceability: Critical for regulatory approval and patient safety.
Supply Chain Security: Due to recent regulations, sourcing from verified and audited suppliers minimizes risks associated with counterfeit or substandard APIs.

Acudial (Phenobarbital) API Sources

Phenobarbital, as part of DIASTAT ACUDIAL, is predominantly manufactured in the same regions as diazepam:

India and China remain the primary sources, with major producers such as:
- Micro Labs Ltd. (India)
- Hubei Sanxin Pharmaceutical Co., Ltd. (China)
European firms such as Merck KGaA produce phenobarbital with high-quality specifications for regulated markets.

Manufacturers must verify that phenobarbital APIs conform to the structural and purity standards outlined in pharmacopoeias, with attention to potential impurities.

Supply Chain and Sourcing Strategies

Given the criticality of API purity:

Vertical integration: Contract manufacturing organizations (CMOs) often maintain proprietary relationships with API producers to safeguard quality.
Supplier qualification audits: Essential for establishing credibility and consistency.
Regional diversification: Mitigating supply disruptions by sourcing from multiple compliant regions.
Long-term partnerships: Facilitate supply stability and negotiated pricing.

Regulatory Implications

Regulatory bodies such as the FDA, EMA, and WHO scrutinize API sources during approval. Manufacturers of DIASTAT ACUDIAL must ensure:

Validation of API suppliers through audits and certifications.
Stability and impurity profile assessment.
Traceability documentation aligning with international standards.

Emerging Trends and Future Outlook

The API market for diazepam and phenobarbital continues evolving driven by:

Stricter global regulatory standards emphasizing API quality assurance.
Increasing demand for cost-effective generics.
Growing scrutiny of supply chain integrity, especially post-COVID-19 disruptions.
Advancements in green manufacturing reducing environmental impact.

Manufacturers and formulators should prioritize transparent sourcing strategies, leveraging regional GMP-certified APIs to meet global quality benchmarks.

Key Takeaways

Major API sources for DIASTAT ACUDIAL include Chinese and Indian manufacturers, with European firms supplying high-purity APIs for regulated markets.
Ensuring API quality demands strict compliance with GMP and pharmacopoeial standards, combined with rigorous supplier qualification.
Supply chain diversification and establishing long-term partnerships mitigate risks associated with geopolitical, regulatory, or logistical challenges.
Regulatory compliance remains crucial; sourcing from certified, audited suppliers accelerates approval processes and assures patient safety.
Emerging trends favor transparency, environmentally conscious manufacturing, and digitalized supply chains to uphold API integrity.

FAQs

1. Are APIs for DIASTAT ACUDIAL readily available from multiple suppliers worldwide?
Yes, major suppliers in China, India, and Europe provide diazepam and phenobarbital APIs, ensuring a diverse global supply chain, provided quality standards are met.

2. What should manufacturers consider when selecting an API supplier for DIASTAT ACUDIAL?
Manufacturers should evaluate GMP compliance, pharmacopoeial adherence, supply stability, certification status, and the supplier’s track record for purity and batch consistency.

3. How does geopolitical instability impact API sourcing for DIASTAT ACUDIAL?
Geopolitical factors can influence supply chain reliability, leading to potential shortages or regulatory scrutiny. Diversifying sources and maintaining regional buffers are strategies to mitigate these risks.

4. Is it possible to manufacture DIASTAT ACUDIAL with APIs from any other country besides China and India?
While China and India dominate API production, high-quality APIs are also manufactured in Europe and the U.S. (for specific markets), ensuring access to regulated, high-purity material globally.

5. What are the recent regulatory trends affecting API sourcing for anticonvulsant medications like DIASTAT ACUDIAL?
Regulatory agencies emphasize transparency, GMP adherence, and supply chain security, pushing manufacturers toward verified, compliant API sources to ensure product safety and compliance.

References

[1] U.S. Pharmacopeia. (2022). Pharmaceutical Supply Chain Report.
[2] IMS Health. (2021). Global API Market Dynamics.
[3] European Medicines Agency. (2022). Guidelines on API quality standards.
[4] WHO. (2020). API Manufacturing and Quality Control.
[5] MarketWatch. (2022). API Manufacturing Regions and Trends.

Bulk Pharmaceutical API Sources for DIASTAT ACUDIAL